Anika Therapeutics (ANIK) EBITDA (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of EBITDA data on file, last reported at -$5.5 million in Q1 2026.

• On a quarterly basis, EBITDA fell 28.1% year-over-year to -$5.5 million in Q1 2026; TTM through Mar 2026 was -$12.3 million, a 78.12% decrease from a year earlier, with the FY2025 full-year figure at -$11.1 million, down 116.64% from the prior year.
• EBITDA for Q1 2026 stood at -$5.5 million, down from $646000.0 in the prior quarter.
• Over the last five years, EBITDA for ANIK reached as high as $24.7 million in Q4 2023 and fell as low as -$12.6 million in Q1 2023.
• Historically, EBITDA has averaged -$1.0 million across 5 years, with a median of -$3.4 million in 2022.
• Across the five-year window, EBITDA jumped 279.8% in 2022 and slumped 3891.36% in 2025, its largest moves.
• Year by year, EBITDA stood at $16.4 million in 2022, then jumped by 50.59% to $24.7 million in 2023, then slumped by 102.85% to -$705000.0 in 2024, then jumped by 191.63% to $646000.0 in 2025, then slumped by 949.54% to -$5.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$5.5 million in Q1 2026, $646000.0 in Q4 2025, and -$3.2 million in Q3 2025.